急性髓性白血病（AML）是骨髓的严重恶性肿瘤，其特征是骨髓前体细胞的异常积聚。Cuproptosis是一种最近发现的依赖于线粒体呼吸的铜依赖性调控细胞凋亡方式。然而，它在AML发展中的参与仍不清楚。本研究分析了与Cuproptosis相关基因与AML患者预后之间的关联。AML病例从TCGA、GEO和TARGET获取，并对与Cuproptosis相关基因所特征的分子亚组以及肿瘤微环境（TME）的相关细胞浸润进行了调查。Cuproptosis评分通过最小绝对收缩和选择运算符（LASSO）工具开发，以评估单个肿瘤样本的Cuproptosis特征。在AML中发现了与Cuproptosis相关的两个不同分子亚组，其预后不同。 TME的细胞浸润实验显示了两个亚型之间的免疫异质性。Cuproptosis评分可以预测肿瘤的亚组、免疫状态和预后。较小的Cuproptosis值标志着良好的预后，而抗PD-1 / PD-L1免疫疗法组表明与相同Cuproptosis组相关的免疫疗效增强。Cuproptosis评分是确定白血病个体的分子亚组、预后、TME细胞浸润特征和免疫治疗效果的重要生物标志物。版权所有 © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios)。

Acute myeloid leukemia (AML) is a severe malignancy of the bone marrow marked by an abnormal accumulation of bone marrow precursors. Cuproptosis is a recently identified type of copper-dependent regulatory cell apoptosis that relies on mitochondrial respiration. However, its participation in the development of AML remains unclear. This study analyzed the association between cuproptosis-related genes and the prognosis of AML patients.Cases of AML were acquired from TCGA, GEO, and TARGET and the molecular subgroups characterized by genes associated with cuproptosis, besides the associated cell infiltration of the tumor microenvironment (TME) were investigated. The cuproptosis score was developed using the minor absolute shrinkage and selection operator (LASSO) tool to evaluate the cuproptosis features of a single tumor sample.Two distinct molecular subgroups related to cuproptosis were discovered in AML with different prognoses. The cellular infiltration assay of TME showed immunological heterogeneity between the two subtypes. The cuproptosis score predicted tumor subgroups, immunity, and prognosis. A small cuproptosis value was marked by a good prognosis, whereas the anti-PD-1/PD-L1 immunotherapy group suggested the same cuproptosis group was related to an elevated immunotherapy potency.The cuproptosis score is a biomarker important for determining the molecular subgroups, prognosis, TME cell infiltration features, and immunotherapeutic efficacy of individuals with leukemia.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.